产品分类/PRODUCT CLASSIFICATION
| 中文名称 | 骨保护蛋白/护骨素抗体 |
| 别 名 | MGC29565; OCIF; OPG; Osteoclastogenesis Inhibitory Factor; TNFRSF 11B; TNFRSF11B; TR 1; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; TR11B_HUMAN. |
| 研究领域 | 肿瘤 细胞生物 免疫学 信号转导 骨髓细胞 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, (predicted: Dog, Cow, ) |
| 产品应用 | WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 43kDa |
| 细胞定位 | 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human OPG:221-300/401 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 产品介绍 | Osteoprotegerin (OPG, or osteoclastogenesis inhibitory factor) is a secretory glycoprotein belonging to TNF receptor superfamily. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. OPG acts as a soluble factor in the regulation of bone mass and may be beneficial in the treatment of osteoporosis with increased osteoclast activity. OPG consists of 401 amino acids with a molecular weight of 44 kDa as a monomer and 90 kDa as a disulphide-linked dimer. Function: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Subunit: Homodimer. Subcellular Location: Secreted. Tissue Specificity: Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. Post-translational modifications: N-glycosylated. Contains sialic acid residues. The N-terminus is blocked. DISEASE: Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal. Similarity: Contains 2 death domains. Contains 4 TNFR-Cys repeats. SWISS: O08712 Gene ID: 4982 Database links: Entrez Gene: 4982 Human Omim: 602643 Human SwissProt: O00300 Human Unigene: 81791 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 护骨素又称护骨因子(osteorotegenin,OPG)、骨保护蛋白、破骨细胞生成抑制因子、骨保护素、破骨细胞抑制生成因子（osteoclastogenesis inhibitory factor，OCIF） OPG属于TNF受体超家族，主要功能是抑制破骨细胞的分化、成熟破骨细胞的骨吸收活性，并诱导其凋亡。 |
| 产品图片 |  Sample:Heart (Mouse) Lysate at 40 ug Kidney (Mouse) Lysate at 40 ug Liver (Mouse) Lysate at 40 ug Primary: Anti-OPG(bs-0431R)at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 43kD Observed band size: 50kD  Sample:Lane 1: Raji (Human) Cell Lysate at 30 ug Lane 2: U251 (Human) Cell Lysate at 30 ug Primary: Anti-OPG (bs-0431R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 55 kD Observed band size: 55 kD  Sample:Stomach (Mouse) Lysate at 40 ug Primary: Anti-OPG (bs- 0431R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 43 kD Observed band size: 60 kD  Sample:Placenta (Mouse) Lysate at 40 ug Liver (Mouse) Lysate at 40 ug Primary: Anti-OPG (bs- 0431R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 43 kD Observed band size: 60 kD  Generously provided by Markus Linder from Medical University Vienna as part of the Bioss Discovery Program. Formalin-fixed, paraffin embedded, and decalcified in EDTA mouse bone labeled with Anti-OPG Polyclonal Antibody, Unconjugated (bs-0431R) at 1:100 followed by conjugation to the secondary antibody and DAB stainingTissue/cell: rat tibia tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-Osteoprotegerin Polyclonal Antibody, Unconjugated(bs-0431R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining |
